Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

2.91
-0.3600-11.01%
Pre-market: 2.970.0599+2.06%07:49 EDT
Volume:6.51M
Turnover:19.91M
Market Cap:494.70M
PE:-1.89
High:3.28
Open:3.28
Low:2.90
Close:3.27
52wk High:4.23
52wk Low:1.72
Shares:170.00M
Float Shares:141.48M
Volume Ratio:1.08
T/O Rate:4.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5420
EPS(LYR):-2.1000
ROE:-93.20%
ROA:-48.19%
PB:2.35
PE(LYR):-1.39

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (CABA), Inspire Medical Systems (INSP) and UnitedHealth (UNH)

TIPRANKS
·
May 06

Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed

TIPRANKS
·
May 05

Cabaletta Bio financing overhang concerns should be addressed, says Cantor

TIPRANKS
·
May 04

Cabaletta Bio Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
May 04

Cabaletta Bio publishes corporate presentation on rese-cel CD19 CAR-T autoimmune disease program

Reuters
·
May 04

Cabaletta Bio Prices $150 Million Stock Offering

MT Newswires Live
·
May 04

Cabaletta Bio Inc - Purchase Price for Common Stock Set at $2.90 per Share

THOMSON REUTERS
·
May 04

Press Release: Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Dow Jones
·
May 04

Cabaletta Bio reports promising RESET-PV and RESET-SLE data

TIPRANKS
·
May 04

Cabaletta Bio reports rese-cel activity without preconditioning in RESET-PV pemphigus trial

Reuters
·
May 04

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Cabaletta Bio (CABA)

TIPRANKS
·
Apr 29

Cabaletta Bio signs 10-year rese-cel commercial supply deal with Cellares

Reuters
·
Apr 28

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-Cel

THOMSON REUTERS
·
Apr 28

Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026

Reuters
·
Apr 28

Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential

TIPRANKS
·
Apr 21

Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans

TIPRANKS
·
Apr 20

Cabaletta Bio posts corporate presentation on CD19 CAR-T candidate rese-cel in autoimmunity

Reuters
·
Apr 20

Cabaletta Bio announces annual shareholder meeting via webcast

Reuters
·
Apr 17

BRIEF-First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform

Reuters
·
Apr 15

H.C. Wainwright Remains a Buy on Cabaletta Bio (CABA)

TIPRANKS
·
Apr 06